Cytokinetics Executive Sells Shares as Street Raises Forecasts
Andrew Callos, Executive Vice President and Chief Commercial Officer of Cytokinetics INC (NASDAQ: CYTK), sold 3,639 shares on March 31, 2026 at $65.00 per share, generating proceeds of $236,535. The transaction comes as the stock trades close to its 52-week high and after a strong one-year return. Several research firms have recently increased thei…